Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Antifungal resistance and tolerance are distinct responses exhibited by fungi when exposed to drugs. While considerable research has focused on azole tolerance in the human pathogen , studies in other fungal species remain limited.

Objective: This study aims to conduct a comparative investigation of the adaptation of the model organism and to fluconazole .

Methods: We performed experiments using laboratory strains of and to evaluate their fluconazole tolerance and resistance under varying temperature conditions. High concentrations of fluconazole were administered, and subsequent changes in fungal phenotypes were analyzed through techniques such as transcriptome analysis and monitoring of petite formation.

Results: Our results revealed that fluconazole tolerance is present in wild-type strains of and is influenced by temperature, albeit in a manner opposite to that observed in . Importantly, when subjected to high concentrations of fluconazole, strains developed resistance without displaying tolerance; all resistant adaptors identified were petites. Chemical induction of petite formation led to an increase in resistance accompanied by a decrease in tolerance.

Conclusion: Transcriptome analysis indicated that petites up-regulated efflux mechanisms while down-regulating most genes. This suggests that, unlike petite-negative , petite-positive swiftly transitions to a petite phenotype upon exposure to fluconazole, resulting in enhanced resistance but diminished tolerance. This evolutionary divergence emphasizes the need for additional studies on fluconazole tolerance in other pathogenic fungi.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086170PMC
http://dx.doi.org/10.3389/fcimb.2025.1519323DOI Listing

Publication Analysis

Top Keywords

fluconazole tolerance
12
fluconazole
8
tolerance
8
tolerance resistance
8
high concentrations
8
concentrations fluconazole
8
transcriptome analysis
8
resistance
6
understanding adaptation
4
adaptation fluconazole
4

Similar Publications

Biofilms are a primary form of device-associated infections and typically exhibit high tolerance to antimicrobial agents. In biofilms formed by multiple microbial species, microorganisms may show even greater tolerance, complicating treatment. There is evidence that meropenem (MEPM) tolerance in is increased in dual-species biofilms with , and effective treatments have not been established.

View Article and Find Full Text PDF

Actinobacteria are one of the largest bacterial phyla. These microbes produce bioactive compounds, such as antifungals, antibiotics, immunological modulators, and anti-tumor agents. Studies on actinobacteria isolated from the Brazilian Savannah biome (Cerrado) are scarce and mostly address metagenomics or the search for hydrolytic enzyme-producing microbes.

View Article and Find Full Text PDF

Interspecies Interactions of Single- and Mixed-Species Biofilms of and .

Biomedicines

August 2025

LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.

Polymicrobial biofilms involving fungal and bacterial species are increasingly recognized as contributors to persistent infections, particularly in the oral cavity. and are two commensals that can turn into opportunistic pathogens and are able to form robust biofilms. : This study aimed to assess the interaction dynamics between these two microorganisms and to evaluate their susceptibility to fluconazole and azithromycin in single- and mixed-species forms.

View Article and Find Full Text PDF

Background: Recurrent vulvovaginal candidiasis develops in 5% to 9% of people assigned female at birth and has a serious impact on quality of life. Oral ibrexafungerp is a first-in-class, nonazole, triterpenoid antifungal approved in the United States for the treatment of postmenarchal females with acute vulvovaginal candidiasis and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Objective: This phase 3 study (CANDLE) describes the efficacy and safety of monthly oral ibrexafungerp vs placebo for reducing the incidence of recurrent vulvovaginal candidiasis.

View Article and Find Full Text PDF

Fungal infections are increasingly concerning, particularly in immunocompromised patients. These patients often suffer from comorbidities and receive multiple, non-antifungal medications. The effects of these co-administered medications on fungal cells - and their potential to influence antifungal drug efficacy - are poorly understood.

View Article and Find Full Text PDF